Hugh Rosen joins Regulus board of directors
Dr. Rosen is a Professor in the Departments of Chemical Physiology & Immunology at The Scripps Research Institute in La Jolla, California where he focuses on the study of lymphocyte trafficking and barrier regulation by signaling lipids, and contributing towards the development of translational infrastructure at TSRI.
He also serves as Chairman of the Committee for Advance Human Therapeutics of TSRI.
Prior to joining The Scripps Research Institute, Dr. Rosen served in various capacities at Merck Research Laboratories, including Executive Director and Therapeutic Area head, and chair of Merck's Anti-bacterial and Anti-fungal Worldwide Business Strategy Team.
Dr. Rosen was the Scientific Founder of Receptos, Inc., now a wholly owned subsidiary of Celgene Corporation, and currently serves on its Scientific Advisory Board. He also serves on the Scientific Advisory Board of ActivX Biosciences Inc.
Dr. Rosen received his M.D. from University of Cape Town and his Ph.D. from University of Oxford. ■
What to read next
LATEST MOVES FROM California
- LPL Financial appoints Scott Seese as CIO
- S&W Seed Company promotes Mark W. Wong to CEO
- Adverum Biotechnologies appoints Athena Countouriotis as CMO
- RF Industries appoints Robert D. Dawson as CEO
- Smith Micro Software appoints Timothy C. Huffmyer as CFO
More inside POST
How board political ideology affects CEO pay Leadership
Negin Khodro to introduce new Megane Companies